Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ARG1 | P05089 | 1/20 | 0.31 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.30 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4783089 | 1.00 | KDM4E (0.32) | KDM4EKMT2AARG1NPFFR1NPFFR2 | |
| SCHEMBL20660355 | 0.89 | KDM4E (0.37) | KDM4EKMT2AARG1NPFFR1NPFFR2 | |
| SCHEMBL17606550 | 0.76 | SMYD3 (0.37) | — | |
| SCHEMBL4793570 | 0.76 | SMYD3 (0.37) | — | |
| SCHEMBL17494329 | 0.74 | CHRM1 (0.34) | — | |
| SCHEMBL3713521 | 0.74 | SMYD3 (0.37) | KDM4EKMT2A | |
| Oxalic Acid SCHEMBL15821260 | 0.74 | P2RX7 (0.30) | — | |
| SCHEMBL16057260 | 0.74 | P2RX7 (0.38) | — | |
| SCHEMBL4776903 | 0.73 | CHRNA7 (0.50) | KDM4EKMT2A | |
| SCHEMBL4776908 | 0.73 | CHRNA7 (0.50) | KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2008012635-A2 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, CCND2, CCND1 | KDM4E 98/4885KMT2A 283/4885ARG1 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.